Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591.

Telix Pharmaceuticals reports positive Phase 3 safety results for its investigational prostate cancer therapy, TLX591-Tx. The post Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Fans of Emmerdale have been left "crying my eyes out" after Cain Dingle's poignant cancer revelation. ITV soap fans will recall that Cain (Jeff Hordley) was shot by John Sugden (Oliver Farnworth) in ...

Researchers have found in a new study that among men with prostate cancer undergoing androgen deprivation therapy, use of oxybutynin 5 mg twice daily significantly reduced the frequency ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

In much-needed good news for the radiopharmaceuticals group, Telix Pharmaceuticals (ASX:TLX) says the first stanza of its “highly innovative” phase III prostate cancer therapeutic trial has come up ...

Former ET co-host John Tesh revealed he that he far exceeded the wildest expectations of doctors who diagnosed him with ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...